Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Simonitsch-Klupp, I; Hauser, I; Ott, G; Drach, J; Ackermann, J; Kaufmann, J; Weltermann, A; Greinix, HT; Skrabs, C; Dittrich, C; Lutz, D; Pötter, R; Mannhalter, C; Lechner, K; Chott, A; Jaeger, U.
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
Leukemia. 2004; 18(1): 146-155.
Doi: 10.1038/sj.leu.2403206
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To define reproducible criteria for subgroups of diffuse large B-cell lymphomas (DLBCL), including lymphomas with plasmablastic/plasmacytoid features (PB/PC-Fs), we investigated 66 DLBCL; the samples were categorized as either centroblastic (CB), immunoblastic (IB) or PB/PC-F applying standardized morphologic criteria. Blinded specimens were reviewed by three independent pathologists. The final consensus classification included 44 CB (67%), seven IB (10%) and 15 PB/PC-F (23%). The interobserver agreement between two centers (Vienna, Würzburg) was 93.5%. Most PB/PC-F were CD20+, cIgM+, MUM-1+, CD138+/-, bcl-6-, corresponding to an activated B-cell phenotype. Immunoglobulin-V(H) gene mutation analysis was consistent with a germinal or postgerminal center-cell origin. By fluorescence in situ hybridization analysis, 11/13 (85%) PB/PC-F had a monoallelic TP53 deletion. The pretreatment characteristics of patients with PB/PC-F included a tendency for more B symptoms, extranodal disease and a higher IPI. Importantly, PB/PC-F were resistant to standard chemotherapy (complete remission rate 47%, relapse rate 71%) and even autologous stem-cell transplantation. The median overall survival (OS) (14 months, P<0.002) and disease-free survival (6 months, P=0.02) were significantly shorter compared to patients with CB and IB. The OS difference was pronounced within the low and low-intermediate IPI risk group (P<0.001). Our data indicate a strong association of plasmablastic/plasmacytoid morphology with TP53 deletions, poor response to chemotherapy and short survival.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antigens, Neoplasm - analysis
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Biological Markers - analysis
- Female -
- Follow-Up Studies -
- Genes, Immunoglobulin -
- Genes, p53 - genetics
- Germinal Center - immunology
- Herpesvirus 4, Human - genetics
- Humans -
- Immunophenotyping -
- In Situ Hybridization, Fluorescence -
- Lymphoma, B-Cell - classification Lymphoma, B-Cell - mortality Lymphoma, B-Cell - pathology
- Lymphoma, Large B-Cell, Diffuse - classification Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - pathology
- Lymphoma, Large-Cell, Immunoblastic - classification Lymphoma, Large-Cell, Immunoblastic - mortality Lymphoma, Large-Cell, Immunoblastic - pathology
- Male -
- Middle Aged -
- Plasma Cells - pathology
- Prognosis -
- RNA, Viral - genetics
- Sequence Deletion -
- Survival Rate -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- DLBCL
- plasmablastic
- TP53
- outcome